Introduction: Although predialysis hemoglobin concentration is affected by interdialytic weight gain (IDWG), the interaction between these parameters is not well understood.

Methods: Using data from the Dialysis Outcomes and Practice Pattern Study in Japan (J-DOPPS) phases 1, 2, 3, 4, and 5, we analyzed patients who underwent maintenance hemodialysis. The exposure variable was hemoglobin concentration, and the effect modifier was IDWG at baseline. These 2 categorical variables were then combined and analyzed. The primary outcome was major adverse cardiovascular events (MACEs). Hazard ratios (HRs) were estimated using a Cox model for the association between exposure and MACEs after adjusting for potential confounders. We examined additive interactions between hemoglobin concentration and IDWG by calculating the relative excess risk due to interaction (RERI), which is defined as a departure from the additivity of effects.

Results: A total of 8234 patients were enrolled. During a median follow-up of 2.1 years, 1062 (12.9%) patients developed MACEs. As the IDWG increased, the lowest point estimation in each IDWG category tended to shift to the lower hemoglobin concentration categories. In IDWG categories of ≥6%, point estimation of MACEs with hemoglobin concentration of ≥10.0 g/dl to <11.0 g/dl was higher than that with hemoglobin concentration of ≥9.0 g/dl to <10.0 g/dl. The RERI was 1.28 (95% confidence interval, 0.28–2.28) between IDWG category of ≥6% and hemoglobin categories of ≥10.0 g/dl to <11.0 g/dl, indicating a synergistic interaction.

Conclusion: The association between hemoglobin concentration and MACEs differed across IDWG. Consideration should be given to the upper limit of hemoglobin concentration in patients with high IDWG.

Correspondence: Yosuke Yamamoto, Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. E-mail: yamamoto.yosuke.5n@kyoto-u.ac.jp

© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
However, the interaction of IDWG and hemoglobin concentrations could not be evaluated because the IDWG was divided into 2 groups, and each group was analyzed as a different group.

Hence, to clarify the impact of IDWG on hemoglobin concentration and cardiovascular events, we conducted a longitudinal study using data from the Dialysis Outcomes and Practice Pattern Study (DOPPS) in Japan. On the assumption that the measured predialysis hemoglobin concentration reflects that the true hemoglobin concentration is diluted with IDWG, we hypothesized that high IDWG as extracellular fluid and high levels of hemoglobin in blood vessels in the closed system of dialysis patients would synergistically promote a volume load and, as a consequence, would have a synergistic interaction with the risk of cardiovascular events.

**METHODS**

**Study Design and Population**

The DOPPS was a prospective cohort study of patients enrolled randomly from a representative sample of dialysis facilities within each participating country. All participants in the DOPPS provided written informed consent before study enrollment. Detailed information on the design of DOPPS has been provided elsewhere.27,28 Our cohort study used the Dialysis Outcomes and Practice Pattern Study in Japan (J-DOPPS), which was approved by a central ethics committee. The current study design was approved by Kyoto University Graduate School and the Faculty of Medicine Kyoto University Hospital Ethics Committee (approval number R1301). Data for the current analysis were obtained from J-DOPPS 1 (1999–2001), J-DOPPS 2 (2002–2004), J-DOPPS 3 (2005–2008), J-DOPPS 4 (2009–2011), and J-DOPPS 5 (2012–2014). The study included patients undergoing maintenance hemodialysis for ≥6 months who were >18 years of age and had available data on hemoglobin concentration and pre- and post-dialysis body weights. We excluded patients with hemoglobin concentrations ≥12.0 g/dl, as we considered this group clinically heterogeneous, with a sample size that was too small to accurately estimate the association.22

**Exposure and Effect Modifier**

The exposure of interest was the hemoglobin concentration, and the effect modifier was IDWG. Hemoglobin concentration and IDWG were assessed in the first session of the week at the enrollment into J-DOPPS. Intradialytic weight loss (IDWL) was used as an IDWG substitute, with the assumption that all the weight gained in the interdialytic interval was lost during the dialysis session, as reported in a previous study.29

We classified hemoglobin concentration into 4 categories by 1.0-g/dl increments (<9.0 g/dl, ≥9.0 g/dl to <10.0 g/dl, ≥10.0 g/dl to <11.0 g/dl, and ≥11.0 g/dl to <12.0 g/dl) and IDWG into 6 categories by 1% increments (<2%, ≥2% to <3%, ≥3% to <4%, ≥4% to <5%, ≥5% to <6%, and ≥6%). The 2 categorical variables were combined and used as exposure categories to evaluate the mechanistic interaction between hemoglobin concentration and IDWG.

**Outcomes**

The primary outcome was major adverse cardiovascular events (MACEs), including acute myocardial infarction (AMI), stroke, and all-cause mortality.30 We included all-cause mortality as a composite outcome because substantial causes of death among patients undergoing hemodialysis were related to cardiovascular events.31 The secondary outcome was all-cause mortality.

**Statistical Analysis**

With regard to the baseline characteristics of patients categorized by hemoglobin concentration, continuous data with a normal distribution were summarized as mean (standard deviation), continuous variables with skewed data were presented as median (interquartile range [IQR]), and dichotomous data were presented as proportion. Unadjusted and multivariable-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for MACEs according to the categories of exposure were calculated using a Cox proportional hazards model. The assumption of the proportional hazards was checked graphically using a log cumulative hazard plots for each outcome according to the categories. The reference category was hemoglobin concentration of ≥10.0 g/dl to <11.0 g/dl and IDWG of ≥3% to <4%, as reported in previous studies.12,32 The multivariable model was adjusted for the following: age, sex, physical function, body mass index, dialysis vintage, cause of end-stage renal

**Figure 1.** Selection process for study population. J-DOPPS, Dialysis Outcomes and Practice Pattern Study in Japan.
Table 1. Baseline characteristics by hemoglobin concentration categories

| Characteristic                        | Total (N = 8234) | <9.0 (n = 1384) | 9.0 to <10.0 (n = 2300) | ≥10.0 to <11.0 (n = 2822) | ≥11.0 to <12.0 (n = 1728) |
|--------------------------------------|------------------|-----------------|-------------------------|--------------------------|---------------------------|
| Age, years                           | 62.5 (12.6)      | 63.2 (12.5)     | 63.0 (12.2)             | 62.2 (12.7)              | 61.7 (12.7)               |
| Male                                 | 60.7             | 54.2            | 59.1                    | 62.3                     | 65.4                      |
| Physical function                    | 29.2 [16.0-65.7] | 29.2 [16.0-42.5]| 29.2 [16.0-65.7]        | 42.5 [29.2-55.7]         | 42.5 [29.2-55.7]          |
| BMI                                  | 20.5 [18.6-22.6] | 20.0 [18.0-22.0]| 20.4 [18.5-22.6]        | 20.7 [18.8-22.7]         | 20.7 [18.9-22.9]          |
| Smoking                              |                  |                 |                         |                          |                           |
| Current smoker                       | 21.6             | 20.3            | 21.2                    | 21.9                     | 22.8                      |
| Past smoker                          | 17.9             | 15.7            | 16.4                    | 19.1                     | 20.1                      |
| Non-smoker                           | 60.5             | 64.0            | 62.4                    | 59.0                     | 57.1                      |
| Diabetes as primary cause of ESRD    | 29.0             | 29.2            | 28.5                    | 28.7                     | 30.0                      |
| Hemodialysis vintage, years          | 5.7 [2.5-11.3]   | 5.4 [2.4-11.0]  | 5.5 [2.5-10.7]          | 5.9 [2.6-11.3]           | 5.9 [2.7-12.4]            |
| Vascular access: AVF                 | 91.2             | 88.2            | 91.8                    | 91.8                     | 92.2                      |
| IDWG, % <2                           | 9.1              | 9.3             | 9.7                     | 8.8                      | 8.6                       |
| ≥2 to <3                             | 13.9             | 12.6            | 13.7                    | 14.7                     | 13.7                      |
| ≥3 to <4                             | 21.9             | 20.0            | 22.0                    | 22.3                     | 22.8                      |
| ≥4 to <5                             | 23.4             | 22.5            | 22.7                    | 23.2                     | 25.2                      |
| ≥5 to <6                             | 16.7             | 15.5            | 17.0                    | 17.3                     | 16.4                      |
| ≥6                                   | 15.0             | 19.9            | 14.7                    | 13.9                     | 13.3                      |
| Coronary arterial disease            | 25.6             | 25.3            | 26.1                    | 25.3                     | 25.9                      |
| Congestive heart failure             | 15.0             | 16.9            | 14.8                    | 14.1                     | 14.9                      |
| Dysrhythmia                          | 21.6             | 22.8            | 22.3                    | 21.3                     | 20.4                      |
| Other cardiovascular disease         | 11.5             | 11.6            | 10.7                    | 11.2                     | 13.0                      |
| Peripheral artery disease            | 15.2             | 16.2            | 14.8                    | 14.8                     | 15.6                      |
| Stroke/TIA                           | 13.7             | 16.3            | 13.2                    | 13.6                     | 12.3                      |
| Gastrointestinal bleeding            | 4.5              | 7.4             | 4.3                     | 4.0                      | 3.2                       |
| Hypertension                         | 70.2             | 67.6            | 70.3                    | 71.9                     | 69.3                      |
| Liver disease                        | 12.5             | 14.9            | 12.4                    | 11.8                     | 11.9                      |
| Lung disease                         | 2.6              | 2.8             | 2.7                     | 2.3                      | 2.6                       |
| Cancer                               | 8.8              | 9.0             | 8.8                     | 8.7                      | 8.9                       |
| Psychiatric disorder                 | 3.0              | 3.3             | 3.1                     | 2.7                      | 3.4                       |
| Neurological disease                 | 6.5              | 8.9             | 5.7                     | 6.5                      | 5.7                       |
| nPCR, g/kg/day                       | 1.01 (0.21)      | 1.00 (0.23)     | 1.01 (0.22)             | 1.01 (0.20)              | 1.01 (0.20)               |
| Single pool Kt/V                     | 1.38 (0.27)      | 1.37 (0.29)     | 1.38 (0.27)             | 1.39 (0.27)              | 1.39 (0.27)               |
| Serum albumin, g/dl                  | 3.8 (0.4)        | 3.6 (0.5)       | 3.7 (0.4)               | 3.8 (0.4)                | 3.8 (0.4)                 |
| Serum total calcium, mg/dl           | 23.0             | 27.7            | 23.4                    | 21.5                     | 21.0                      |
| <8.4 to <10.0                        | 63.6             | 58.9            | 63.6                    | 64.6                     | 65.9                      |
| Serum phosphorus, mg/dl <3.5         | 5.8              | 9.9             | 6.2                     | 4.5                      | 4.2                       |
| ≥3.5 to <6.0                         | 59.1             | 58.0            | 60.3                    | 59.6                     | 57.6                      |
| ≥6.0 to <240                         | 35.1             | 32.2            | 33.6                    | 35.9                     | 38.2                      |
| intact PTH, pg/ml <60                | 26.5             | 29.5            | 28.2                    | 25.1                     | 24.5                      |
| ≥240                                 | 51.0             | 46.4            | 49.4                    | 53.9                     | 51.5                      |
| Fe, µg/dl                            | 58 [43-77]       | 52 [37-71]      | 56 [41-75]              | 60 [48-79]               | 61 [46-80]                |
| Ferritin, ng/ml                      | 120 [47-281]     | 138 [50-366]    | 120 [48-286]            | 117 [48-267]             | 108 [44-245]              |
| TIBC, µg/dl                          | 241 [207-280]    | 236 [196-282]   | 237 [204-282]           | 242 [209-278]            | 246 [214-282]             |
| Pre-dialysis systolic BP, mmHg       | 150.9 [23.4]     | 151.3 [24.2]    | 151.5 [22.8]            | 150.9 [23.4]             | 149.8 [23.5]              |
| Antiprotein drug for drug            | 44.3             | 43.0            | 42.6                    | 45.9                     | 45.0                      |
| Anticoagulant drug                   | 6.0              | 5.4             | 5.0                     | 6.3                      | 7.4                       |
| RASi                                  | 51.4             | 47.2            | 51.6                    | 52.7                     | 52.3                      |
| Iron use                             | 31.9             | 26.1            | 30.3                    | 33.3                     | 36.6                      |
| ERI, IU/week/kg/dl                   | 5.7 [3.0-10.1]   | 8.3 [4.9-13.0]  | 5.8 [3.5-10.2]          | 5.3 [2.8-9.5]            | 4.3 [1.9-8.0]             |

Values for categorical variables are given as percentages. Values for continuous variables are given as mean (standard deviation) or as median [interquartile range]. AVF, arteriovenous fistula; BMI, body mass index; BP, blood pressure; ERI, erythropoietin-stimulating agents resistance index; ESRD, end-stage renal disease; IDWG, interdialytic weight gain; nPCR, normalized protein catabolic rate; PTH, parathyroid hormone; TIA, transient ischemic attack; TIBC, total iron binding capacity; RASI, renin-angiotensin system inhibitor.
vascular disease, lung disease, liver disease, cancer, gastrointestinal bleeding, neurological disorder, psychiatric disorder, anticoagulant drug, antiplatelet drug, renin–angiotensin system inhibitor (RASI), iron use, and erythropoietin-stimulating agent resistance index (ERI). Physical function was assessed using the physical function subscale of the Medical Outcome Study 12-Item Short-Form with norm-based scoring. The ERI was derived by dividing weekly ESA dose by postdialysis body weight (kg) and hemoglobin concentration (g/dl). Darbepoetin alfa and epoetin beta pegol doses were converted to ESA dose (IU/wk) using a dose conversion ratio (epoetin:darbepoetin alfa:epoetin beta pegol = 200:1:1). These variables were based on an a priori clinical judgment and existing studies. We used robust variance estimates to consider cluster effects at the facility level.

We examined additive interactions between hemoglobin concentration and IDWG, as additive interactions more closely correspond to tests for mechanistic interaction rather than multiplicative interaction. We estimated the relative excess risk due to interaction (RERI). The RERI between 2 factors (X and Z) is defined as departure from additivity of effects and is calculated as follows using adjusted HRs:

$$RERI = HR_{XZ} - HR_X - HR_Z + 1$$

RERI < 0, RERI = 0, and RERI > 0 indicate an antagonistic interaction, absence of interaction, and synergistic interaction, respectively.

In previous studies, mortality and cardiovascular events tended to be lower as hemoglobin concentration increased between the range of 9 g/dl to 12 g/dl. Our hypothesis was that hemoglobin concentration increments would promote a volume load for higher IDWG, and we expected the HR of MACEs to start increasing at a certain hemoglobin concentration in the high IDWG category. Therefore, we evaluated RERI in the IDWG category when HR of MACEs increased along with hemoglobin concentration increments.

Missing covariates were replaced using the multiple imputations with chained equations method, assuming...
that analyzed data were missing at random. These estimates from 20 imputation datasets were combined using the Rubin rules.

All analyses were performed using Stata version 15.0 software (StataCorp, College Station, TX). P values <0.05 were considered statistically significant.

RESULTS
Baseline characteristics
A total of 8234 patients were enrolled in the study (Figure 1). The mean age was 62.5 years, 60.7% were male, 29.0% had ESRD caused by diabetes, and the median duration of dialysis therapy was 5.7 years (Table 1). Patients with lower hemoglobin concentrations were older and included a higher proportion of female patients, nonsmokers, and patients with IDWG ≥6%, dysrhythmia, stroke/TIA, gastrointestinal bleeding, serum total calcium <8.4 mg/dl, and serum phosphorus <3.5 mg/dl. In contrast, patients with higher hemoglobin concentrations exhibited longer dialysis vintage, higher proportion of serum phosphorus ≥6.0 mg/dl and iron use, and lower ERI.

Association of Hemoglobin Concentration With MACEs and Mortality by IDWG Categories
During a median follow-up of 2.1 years, 1062 patients (12.9%) developed MACEs. The incidence rate of MACEs was 6.3 per 100 person-years. Incidences of MACEs by each category of IDWG and hemoglobin concentration are shown in Table 2. Details of MACEs are shown in Table 3. Associations among the 24 categories of IDWG, hemoglobin concentration, and MACEs are shown in Tables 4 and 5. As the IDWG increased, the lowest point estimation in each IDWG category tended to shift to lower hemoglobin concentration categories (Table 5). In the IDWG category of ≥6%, the point estimation with a hemoglobin concentration of ≥10.0 g/dl to <11.0 g/dl and IDWG of ≥3% to <4% was lower than that with a hemoglobin concentration of ≥9.0 g/dl to <10.0 g/dl.

With regard to mortality, during a median follow-up of 2.1 years, 894 patients (10.9%) died, and the mortality rate

Table 4. Unadjusted hazard ratios for MACEs and mortality by hemoglobin concentration and IDWG categories

| MACEs | IDWG (%) | <2 | ≥2 to <3 | ≥3 to <4 | ≥4 to <5 | ≥5 to <6 | ≥6 |
|-------|----------|----|----------|----------|----------|----------|----|
| Hemoglobin concentration (g/dl) | <9.0 | 4.41 (2.84-6.82) | 2.56 (1.72-3.80) | 2.12 (1.41-3.17) | 2.26 (1.47-3.48) | 2.64 (1.72-4.06) | 1.82 (1.21-2.74) |
|       | ≥9.0 to <10.0 | 2.02 (1.27-3.20) | 1.85 (1.25-2.74) | 1.58 (1.15-2.17) | 1.31 (0.91-1.88) | 1.30 (0.88-1.91) | 1.60 (1.11-2.32) |
|       | ≥10.0 to <11.0 | 1.34 (0.90-1.99) | 1.38 (0.91-2.02) | Reference | 1.32 (0.91-1.90) | 1.27 (0.87-1.85) | 1.99 (1.34-2.96) |
|       | ≥11.0 to <12.0 | 2.26 (1.47-3.48) | 1.13 (0.69-1.84) | 1.44 (0.99-2.08) | 1.44 (1.01-2.06) | 1.48 (0.98-2.27) | 1.37 (0.88-2.13) |

| Mortality | IDWG (%) | <2 | ≥2 to <3 | ≥3 to <4 | ≥4 to <5 | ≥5 to <6 | ≥6 |
|-----------|----------|----|----------|----------|----------|----------|----|
| Hemoglobin concentration (g/dl) | <9.0 | 5.05 (3.33-7.64) | 2.73 (1.77-4.21) | 2.16 (1.41-3.29) | 2.35 (1.50-3.68) | 2.56 (1.63-3.98) | 1.90 (1.25-2.90) |
|       | ≥9.0 to <10.0 | 2.33 (1.47-3.88) | 2.02 (1.34-3.06) | 1.54 (1.10-2.18) | 1.34 (0.93-1.92) | 1.39 (0.89-2.15) | 1.68 (1.16-2.44) |
|       | ≥10.0 to <11.0 | 1.48 (0.95-2.32) | 1.52 (1.04-2.22) | Reference | 1.26 (0.84-1.84) | 1.21 (0.79-1.84) | 2.04 (1.32-3.15) |
|       | ≥11.0 to <12.0 | 2.38 (1.45-3.82) | 1.27 (0.74-2.20) | 1.41 (0.94-2.13) | 1.19 (0.80-1.77) | 1.48 (0.94-2.31) | 1.41 (0.89-2.22) |

Values in boldface type indicate statistically significant values. The reference was hemoglobin concentration of ≥10.0 g/dl to <11.0 g/dl and IDWG of ≥3% to <4%.

Table 5. Adjusted hazard ratios for MACEs and mortality by hemoglobin concentration and IDWG categories

| MACEs | IDWG (%) | <2 | ≥2 to <3 | ≥3 to <4 | ≥4 to <5 | ≥5 to <6 | ≥6 |
|-------|----------|----|----------|----------|----------|----------|----|
| Hemoglobin concentration (g/dl) | <9.0 | 2.17 (1.38-3.43) | 1.42 (0.88-2.29) | 1.32 (0.87-2.00) | 1.71 (1.13-2.60) | 2.26 (1.45-3.51) | 1.60 (1.01-2.52) |
|       | ≥9.0 to <10.0 | 1.31 (0.82-2.11) | 1.50 (0.96-2.37) | 1.45 (1.01-2.08) | 1.27 (0.87-1.85) | 1.26 (0.83-1.92) | 1.48 (0.94-2.32) |
|       | ≥10.0 to <11.0 | 1.06 (0.68-1.61) | 1.23 (0.80-1.88) | Reference | 1.33 (0.89-2.01) | 1.36 (0.91-2.04) | 2.31 (1.55-3.44) |
|       | ≥11.0 to <12.0 | 1.98 (1.25-3.31) | 1.31 (0.81-2.12) | 1.26 (0.84-1.90) | 1.44 (0.98-2.13) | 1.79 (1.11-2.90) | 1.58 (0.94-2.67) |

| Mortality | IDWG (%) | <2 | ≥2 to <3 | ≥3 to <4 | ≥4 to <5 | ≥5 to <6 | ≥6 |
|-----------|----------|----|----------|----------|----------|----------|----|
| Hemoglobin concentration (g/dl) | <9.0 | 2.27 (1.42-3.61) | 1.44 (0.91-2.29) | 1.27 (0.81-1.98) | 1.70 (1.10-2.63) | 2.13 (1.34-3.40) | 1.69 (1.08-2.65) |
|       | ≥9.0 to <10.0 | 1.42 (0.89-2.27) | 1.55 (0.97-2.48) | 1.36 (0.93-1.99) | 1.27 (0.87-1.88) | 1.36 (0.84-2.17) | 1.55 (0.92-2.47) |
|       | ≥10.0 to <11.0 | 1.10 (0.70-1.75) | 1.33 (0.88-2.01) | Reference | 1.23 (0.80-1.88) | 1.27 (0.82-1.97) | 2.28 (1.54-3.40) |
|       | ≥11.0 to <12.0 | 2.00 (1.19-3.35) | 1.36 (0.82-2.25) | 1.14 (0.71-1.82) | 1.15 (0.75-1.74) | 1.79 (1.08-2.98) | 1.69 (0.93-2.76) |

Values in boldface type indicate statistically significant values. The reference was hemoglobin concentration of ≥10.0 g/dl to <11.0 g/dl and IDWG of ≥3% to <4%. The multivariable-adjusted model was adjusted for age, sex, physical function, body mass index, vintage, cause of end-stage renal disease, vascular access, smoking, systolic blood pressure, single pool Kt/V, nPCR, serum albumin, calcium, phosphorus, intact PTH, Fe, TIBC, ferritin, hypertension, coronary heart disease, congestive heart failure, dysrhythmia, other cardiovascular disease, stroke/TIA, peripheral vascular disease, lung disease, liver disease, cancer, gastrointestinal bleeding, neurological disorder, psychiatric disorder, anticoagulant drug, antibiotic drug, RASI, iron use, and ERI, erythropoietin-stimulating agent resistance index; MACEs, major adverse cardiovascular events; nPCR, normalized protein catabolic rate; PTH, parathyroid hormone; RASI, renin–angiotensin system inhibitor; TIA, transient ischemic attack; TIBC, total iron binding capacity.

*MACEs included acute myocardial infarction, stroke, and all-cause mortality.
was 5.3 per 100 person-years. The incidence rates of mortality by each category of IDWG and hemoglobin concentration are shown in Table 2. The associations between the 24 categories of IDWG, hemoglobin concentration, and mortality are shown in Tables 4 and 5. Similarly, as the IDWG increased, the lowest point estimates in each IDWG category tended to shift to lower hemoglobin concentration categories (Table 5). In the IDWG category of ≥6%, point estimation with hemoglobin concentration of ≥10.0 g/dl to <11.0 g/dl and IDWG of ≥6% was higher than that with hemoglobin concentration of ≥9.0 g/dl to <10.0 g/dl.

**Interaction Between Hemoglobin Concentration and IDWG on MACEs and Mortality**

Figure 2a depicts adjusted HRs for MACEs by hemoglobin concentration of ≥9.0 g/dl to <10.0 g/dl and IDWG of ≥3% to <4%. Values in boldface type are statistical significant values. RERI, relative excess risk due to interaction.

---

**Figure 2.** Effect of interdialytic weight gain (IDWG) on hazard ratios (HRs) for the association between hemoglobin concentration and (a) major adverse cardiovascular events (MACEs; includes acute myocardial infarction, stroke, and all-cause mortality) and (b) mortality. HRs of hemoglobin concentration of ≥9.0 g/dl to <10.0 g/dl and of ≥10.0 g/dl to <11.0 g/dl on (a) MACEs and (b) mortality by IDWG. Reference was hemoglobin concentration of ≥10.0 g/dl to <11.0 g/dl and IDWG of ≥3% to <4%. Values in boldface type are statistical significant values. RERI, relative excess risk due to interaction.
dl to <11.0 g/dl and IDWG. The RERI was 1.28 (95% CI = 0.28–2.28) between the IDWG category of ≥6% and hemoglobin categories of ≥10.0 g/dl to <11.0 g/dl with respect to MACEs, indicating a synergistic interaction.

Similarly, the RERI was 1.09 (95% CI = 0.05–2.13) between the IDWG category of ≥6% and hemoglobin category of ≥10.0 g/dl to <11.0 g/dl with respect to mortality, also indicating a synergistic interaction (Figure 2b).

**DISCUSSION**

In this study, we observed that the lowest point estimation of MACEs in each IDWG category tended to shift to lower hemoglobin concentration categories as the IDWG increased. The point estimation of MACEs with a hemoglobin concentration of ≥10.0 g/dl to <11.0 g/dl and IDWG of ≥6% was higher than that with a hemoglobin concentration of ≥9.0 g/dl to <10.0 g/dl and IDWG of ≥6%. The RERI was 1.28 (95% CI = 0.28–2.28) between IDWG categories of ≥6% and hemoglobin categories of ≥10.0 g/dl to <11.0 g/dl with respect to MACEs, indicating a synergistic interaction. With respect to mortality, similar results were obtained.

Previous studies have shown that cardiovascular events risk decreased as hemoglobin concentration increased between 9 g/dl and 12 g/dl. However, it was noteworthy that the association between hemoglobin concentration and MACEs differed across IDWG by stratification, especially in IDWG categories of ≥6%. Potential mechanisms of increased cardiovascular event risk with higher hemoglobin concentration are as follows: (i) effects of hemoglobin itself, (ii) effects of erythropoiesis-stimulating agent treatment, (iii) erythropoiesis-stimulating agent hypo-responsiveness, (iv) effects of iron treatment, (v) increased blood volume and pressure, and (vi) other mechanisms. This study may support the fifth mechanism listed above (i.e., increased blood volume and pressure). In the present study, we presumed that predialysis hemoglobin concentration was in a state in which unmeasured true hemoglobin concentration was diluted by IDWG, and it was possible that the true hemoglobin concentration was higher than the measured hemoglobin concentration for high IDWG. Therefore, in categories of hemoglobin concentration ranging from ≥10.0 g/dl to <11.0 g/dl and IDWG of ≥6%, the true hemoglobin concentration may have been higher than the optimal hemoglobin concentration, promoting volume overload and increasing the risk of cardiovascular events.

The true hemoglobin concentration cannot be measured in patients undergoing HD. Predialysis hemoglobin concentration is affected by IDWG, and postdialysis hemoglobin concentration is affected by the balance between the ultrafiltration volume and the refill volume. In current predialysis measurement practices, consideration of IDWG in the interpretation of predialysis hemoglobin concentration may contribute to reduction of cardiovascular event risk, even if the true hemoglobin concentration in patients receiving HD is unknown.

Considering the mechanism of volume load, a previous study reported that the risk of cardiovascular events increased as IDWG increased. However, in our study, the risk of cardiovascular events was higher in the low IDWG and low hemoglobin concentration group. Previous studies have shown that inflammatory factors are associated with anemia, cardiovascular events, and prognosis. In addition, it is well known that both inflammatory factors and IDWG are nutritional indicators that affect cardiovascular events and prognosis. Therefore, we might have overestimated the synergistic association between both low hemoglobin concentration and low IDWG and higher cardiovascular risk, because we could not adjust for the inflammatory factors. Although there were effects of residual confounders, in the stable population of hemoglobin concentration from 10 to 11 g/dl, there was a trend toward increased cardiovascular event risk as the IDWG increased. Therefore, we considered that the effects of residual confounders were likely to be small in the groups.

Furthermore, these results support the concept of “volume first,” whereby volume control is considered the primary goal of dialysis care. This study did not directly establish this priority between hemoglobin concentration and IDWG, but interpretation of hemoglobin concentration is facilitated under good fluid management. Hemoglobin concentration management is performed mainly by dialysis physicians, whereas IDWG management depends predominantly on patients. Although the RERI estimate was not large, it would be undesirable for hemoglobin treatment by dialysis physicians’ practices to lead to patient harm. Attention should be paid to IDWG before attempting to control hemoglobin concentration within guideline target ranges.

The major strengths of this study are as follows. This is the first study to evaluate the interaction between hemoglobin concentration and IDWG. Second, we defined exposure categories on the basis of 2 categorical factors, which enabled us to examine the separate and combined effects of these components and their additive interaction by calculating the RERI. Third, this research was a prospective study with a large sample size, which was representative of most Japanese dialysis settings.
There were also several limitations to this study. First, patients may have transferred into different categories, as baseline data were used to define exposure categories in this cohort. Second, caution should be exercised when extrapolating our results because of the differences in sampling timing from that of other countries. Hemoglobin concentration is assessed in the mid-week dialysis session in almost all countries. Weight gain in the mid-week dialysis session is generally less than that in the first dialysis session. Therefore, the influence of weight gain on the interpretation of predialysis hemoglobin concentration may be attenuated. However, our results may be extrapolated to populations with high weight gain in the mid-week dialysis session. Further studies considering the timing of measurements are warranted. Third, there were unmeasured confounding factors. In this study, we lacked information on residual renal function and inflammatory factors throughout all phases. However, we minimized the effects by excluding patients undergoing maintenance HD for <6 months and by adjusting for related factors, such as dialysis vintage, ferritin, and albumin.

In conclusion, our study is the first to demonstrate that the association between hemoglobin concentration and MACEs differs across IDWG. Attention should be paid to hemoglobin concentration in patients with high IDWG even if it falls within the target ranges of the guidelines.

**DISCLOSURE**

TA has been a scientific advisor or consultant for Astellas, JT Pharmaceuticals, Torii Pharmaceutical, Kyowa Kirin, Nipro Medical, Ono Pharmaceutical, Bayer HealthCare, Fuso Pharmaceutical, GlaxoSmithKline, and Kissei Pharmaceutical; and has received lecture fees from Chugai Pharmaceutical, Kyowa Kirin, Bayer HealthCare, Torii Pharmaceutical, Kissei Pharmaceutical and Ono Pharmaceutical. All the other authors declare no competing interests.

**ACKNOWLEDGMENTS**

The Dialysis Outcomes and Practice Patterns Study (DOPPS) is coordinated by Arbor Research Collaboration for Health, and J-DOPPS is supported by scientific research grants from Kyowa Kirin Co., Ltd., without any restrictions on publication. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We appreciate the cooperation of the patients and facilities participating in the J-DOPPS.

**REFERENCES**

1. Grunze M, Kohlmann M, Mulligan M, et al. Mechanisms of improved physical performance of chronic hemodialysis patients after erythropoietin treatment. Am J Nephrol. 1990;10(suppl 2):15–23.
2. McMahon LP, McKenna MJ, Sangkabutra T, et al. Physical performance and associated electrolyte changes after haemodialysis normalization: a comparative study in hemodialysis patients. Nephrol Dial Transplant. 1999;14:1182–1187.
3. Moreno F, Sanz-Guajardo D, López-Gómez JM, et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol. 2000;11:335–342.
4. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol. 2001;12:2797–2806.
5. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int. 2004;65:626–633.
6. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19:121–132.
7. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:94–111.
8. Robinson BM, Joffe MM, Berns JS, et al. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int. 2005;68:2323–2330.
9. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–1191.
10. Walker AM, Schneider G, Yeaw J, et al. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol. 2006;17:2293–2298.
11. Akizawa T, Pisoni RL, Akiba T, et al. Japanese hemodialysis anaemia management practices and outcomes (1999–2006): results from the DOPPS. Nephrol Dial Transplant. 2008;23:3643–3653.
12. Akizawa T, Saito A, Geijo F, et al. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients. Ther Apher Dial. 2014;18:404–413.
13. Johansen KL, Finkelstein FO, Revicki DA, et al. Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transplant. 2012;27:2418–2425.
14. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590.
15. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident
hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180–2189.

16. Singh AK, Szczek L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098.

17. Pisoni RL, Gillespie BW, Dickinson DM, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis. 2004;44(5 suppl 2):7–15.

18. Bellizzi V, Minutolo R, Terracciano V, et al. Intra- and postdialytic changes of haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381–388.

19. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23–33.

20. McMurray JJV, Parfrey PS, Adamson JW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279–335.

21. Locatelli F, Bârâpy P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28:1346–1359.

22. Yamamoto H, Nishi S, Tomo T, et al. 2015 Japanese Society for Dialysis Therapy: Guidelines for renal anemia in chronic kidney disease. Ren Replace Ther. 2017;3:36.

23. Movilli E, Pertica N, Camerini C, et al. Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. Am J Kidney Dis. 2002;39:850–853.

24. Minutolo R, De Nicola L, Bellizzi V, et al. Intra- and postdialytic changes of haemoglobin concentrations in nonanaemic haemodialysis patients. Nephrol Dial Transplant. 2003;18:2606–2612.

25. Bellizzi V, Minutolo R, Terracciano V, et al. Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Am J Kidney Dis. 2002;40:549–555.

26. Toida T, Iwakiri T, Sato Y, et al. Relationship between hemoglobin levels corrected by interdialytic weight gain and mortality in Japanese hemodialysis patients: Miyazaki Dialysis Cohort Study. PLoS One. 2017;12:e0169117.

27. Young EW, Goodkin DA, Mapes DL, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int. 2000;57[suppl 74]:S74–S81.

28. Pisoni RL, Gillespie BW, Dickinson DM, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis. 2004;44(5 suppl 2):7–15.